Sansure Biotech Inc. (SHA:688289)

Sansure Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,863	4,590	4,233	3,213	2,636	2,591
Trading Asset Securities	141.9	139.67	548.28	2,451	2,046	1,601
Cash & Short-Term Investments	4,005	4,730	4,782	5,664	4,683	4,192
Cash Growth	-12.34%	-1.09%	-15.57%	20.95%	11.70%	2433.03%
Accounts Receivable	749.11	560.69	692.26	1,298	807.66	546.4
Other Receivables	24.06	27.58	23.49	82.41	14.3	17.55
Receivables	773.17	588.27	715.75	1,381	821.95	563.94
Inventory	423.57	392.75	376.63	355.31	369.5	276.74
Other Current Assets	102.84	78.7	75.45	125.83	92.09	50
Total Current Assets	5,305	5,790	5,950	7,525	5,966	5,083
Property, Plant & Equipment	1,272	1,113	1,043	785.27	481.03	216.54
Long-Term Investments	1,272	1,096	974.33	657.43	513.23	102.51
Goodwill	800.33	7.66	7.66	-	-	-
Other Intangible Assets	485.9	334.67	283.28	79.12	45.55	31.23
Long-Term Deferred Tax Assets	86.87	69.28	73.82	69.62	25	17.22
Long-Term Deferred Charges	177.9	147.27	97.05	46.7	16.26	4.16
Other Long-Term Assets	64.18	47.04	25.16	10.19	43.08	-
Total Assets	9,464	8,604	8,454	9,174	7,090	5,454
Accounts Payable	323.29	225.78	271.14	586.26	188.82	208.05
Accrued Expenses	65.82	290.03	363.33	622.39	231.82	237.88
Short-Term Debt	74.28	9	9	-	-	55
Current Portion of Leases	3.09	5.28	11.1	14.26	8.49	-
Current Income Taxes Payable	26.29	0.21	17.66	145.25	80.16	104.17
Current Unearned Revenue	24.48	64.55	32.81	53.11	78.64	62.47
Other Current Liabilities	570.58	159.94	214.12	150.45	76.01	21.11
Total Current Liabilities	1,088	754.8	919.15	1,572	663.93	688.69
Long-Term Debt	1,015	396.65	-	-	-	-
Long-Term Leases	10.04	11.92	18.21	13.6	6.41	-
Long-Term Unearned Revenue	38.83	39.88	32.49	30.53	25.68	18.95
Long-Term Deferred Tax Liabilities	92.02	54.75	59.45	19.04	13.01	1.31
Other Long-Term Liabilities	-	-	-	26.09	-	-
Total Liabilities	2,244	1,258	1,029	1,661	709.03	708.95
Common Stock	579.39	582.39	588.46	588.46	400	400
Additional Paid-In Capital	1,602	1,702	1,908	1,914	2,065	2,055
Retained Earnings	5,077	5,194	5,177	5,371	4,082	2,288
Treasury Stock	-164.89	-274.29	-515.33	-392.6	-200.01	-
Comprehensive Income & Other	37.26	39.01	43.26	19.36	21.71	2.12
Total Common Equity	7,131	7,243	7,201	7,501	6,369	4,745
Minority Interest	89.33	102.56	223.64	12.16	12.43	-
Shareholders' Equity	7,220	7,346	7,425	7,513	6,381	4,745
Total Liabilities & Equity	9,464	8,604	8,454	9,174	7,090	5,454
Total Debt	1,103	422.85	38.31	27.86	14.9	55
Net Cash (Debt)	2,902	4,307	4,743	5,636	4,668	4,137
Net Cash Growth	-29.78%	-9.20%	-15.83%	20.74%	12.83%	2399.80%
Net Cash Per Share	4.31	7.35	8.09	9.63	7.93	7.49
Filing Date Shares Outstanding	574.18	573.72	573.52	578.69	592	592
Total Common Shares Outstanding	574.18	573.72	572.21	578.69	592	592
Working Capital	4,217	5,035	5,030	5,954	5,302	4,394
Book Value Per Share	12.42	12.62	12.59	12.96	10.76	8.02
Tangible Book Value	5,845	6,901	6,910	7,421	6,323	4,714
Tangible Book Value Per Share	10.18	12.03	12.08	12.82	10.68	7.96
Buildings	-	834.41	826.53	344.51	231.04	177.15
Machinery	-	607.96	436.62	322.65	270.13	142.76
Construction In Progress	-	3.58	4.59	267.76	110.45	1.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.